News & Updates

Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.

Children with rotavirus infection are at risk of developing gastroenteritis with severe but self-limiting neurological manifestations, reveals a study.

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).